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Probiotics and functional food: an introduction 
It is hard not to notice the little bottles of ‘friendly bacteria’, or ‘probiotics’ 
colonising more and more supermarket shelf space. One lead company in the 
probiotic little bottle market claims 25 million people across 20 countries as daily 
users of their products1. In the UK, from the first introduction of 65ml bottles of 
sweetened fermented drink containing probiotic bacteria in 1996, other 
companies and products have entered a growing market for probiotic little 
bottles, probiotic yoghurts, probiotic smoothies and so on,  such that an 
estimated 3.5 million UK residents consume some form of probiotic product on a 
daily basis (Senok, Ismaeel and Botta, 2005).  The success of probiotic little bottles 
is generally regarded as a factor of their reputed health benefits and as consistent 
with a more general shift in supermarkets supply of products that offer added 
health benefits – collectively known as functional foods in industry circles 
(Heasman and Mellentin, 2001). While the category functional foods currently 
has no legal status in the UK, it is used within industry to describe foods such as 
cholesterol lowering margarines with added plant stanols, omega-3 fortified 
drinks and other products where particular health gains are aligned with 
                                                     
 
 
 
 
1  Yakult company brochure, 2006 
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ingredients deemed to be additional to the food itself (Lehenkari, 2003; Sibbel, 
2007). 
 
The continued and rapid growth of these products in supermarkets raises, for us, 
questions about how to account for consumers’ choice of probiotics. The case 
study provides an opportunity to reflect on the ways in which ‚raw biological 
vitality‛, in this case bacteria as fragments of more complex systems, may be 
mobilised for new health uses and given a marketable exchange value –  what 
Catherine Waldby terms biovalue (Waldby, 2002: 313). The  success of probiotics  
raises further questions about the new ways in which health-related biovalue is 
mobilised within markets and mobilizes ‘biologies and selves’ (Brown, 2006; 
Waldby, 2002). First, their consumption for supposed health gains appears at 
odds with the weak scientific evidence supporting the healthy messages such 
products convey (Tannock, 1999). Whilst advertisements for probiotics promote 
‚vitality‛, a ‚healthy digestive system‛,  ‚wellbeing‛ and ‚balance‛,  the 
evidence that probiotics work to produce such effects, as recent reviews suggest, 
is far from well accepted (Gibson, Rouzaud and Brostoff, 2005; Senok et al., 2005; 
Walker and Buckley, 2006). Second, probiotics are the most successful products 
in the category of functional foods (Sloan, 2004) with estimates that the probiotic 
sector will continue to grow by as much as 40% (Daniells, 2006 ). Not all 
functional foods have met with industry expectations of success, leaving some 
developers and investors out of pocket (Heasman et al., 2001). While 
controversies over their effectiveness play out in scientific debates,  in the 
supermarket these concerns appear to have little bearing on their popularity as 
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consumer products, and moreover, with indications that they are consumed 
more as an ‘article of faith’ and less by the ill than by the healthy - thus raising 
for some the question of why they are consumed at all (Tannock, 1999). Third, 
the development of  probiotics occurs in much more complex and contested 
terrain of ‘facts and myths’ about their possible uses and effectiveness (Senok et 
al., 2005). Interest in probiotics is more widespread than simply the development 
of new food products. Both scepticism and promise about what they are or what 
they are claimed to do is evident across fields as diverse as animal nutrition, 
aquaculture, biotechnology, food technology and medical sciences (Balcazar et 
al., 2006; Holzapfel, 2005; Vanbelle, Teller and Focant, 1989).  
 
Pobiotics describes a new category whose most widely quoted contemporary 
definition is ‚live microorganisms, which, when administered in adequate 
amounts, confer a health benefit on the host‛ (World Health Organisation, 2001: 
5). Like the functional foods category, the link to health is assumed as the 
primary motivation that underscores their use. However, given controversies 
over facts and myths about their efficacy, does the linkage with health imply 
(and perhaps produce) a more prospective hope about them than the ‘truth’ 
provides? Alternatively, what might hope and truth reveal about the context of 
probiotic developments? In this paper we address the later concern, and rather 
than addressing, as so many others have done, the question of probiotics efficacy, 
following the work of Moreira and Pallandino (2005) we trace and consider the 
significance of hope and truth in relation to them.  
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On hope and truth 
We begin by placing our research within recent literature documenting an 
apparent shift in the epistemological basis of modern bioscience away from 
rationalistic authority towards a much greater emphasis on investment in less 
certain but hopeful futures (Brown, 2006; Moreira and Palladino, 2005; Novas, 
2006). Various empirical examples may be cited to demonstrate bioscience 
interest in hopeful technologies and techniques –  predictive medicine, 
nanotechnology,  transgenics. However it is not the proliferation of such 
innovations that provide evidence for a shift to hope, but observations of the 
conditions for its emergence.  These conditions can be seen to involve a shift in 
what counts , and how it counts, as knowledge in biosciences. 
 
Drawing on poststructuralist methodologies and sociologies of science literatures 
regimes of power/knowledge enable and produce certain ways of viewing the 
world (Foucault, 1984, 1989; Petersen and Bunton, 1997). Such methodological 
approaches share a concern with the ‚more or less organized or routinized ways 
of doing things that manifest an immanent logic of reason of their own‛ (Dean, 
1999). Rejecting an absolutist account of knowledge refocuses attention on 
understanding how knowledge (and power) is dependent on particular regimes, 
practices and heterogeneous networks. Different regimes of knowledge provide a 
substrate of intelligibility, in this case rendering investment in the future as a 
normal state of affairs; and thereby affecting the way the future unfolds.  
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A regime of truth orients towards fabricating ‘proofs’ and knowledge robustness, 
whilst the regime of hope is concerned with the fabrication of expectations and 
future possibilities (Brown and Michael, 2002; Moreira et al., 2005). Regimes of 
truth may be said to focus attention on ‘what is known, rather than what can be’, 
while investments in a regimes of hope are in future possibilities of truth, 
deferring truth and rendering the present open to various efforts in securing the 
uncertainty of the present as an acceptable state of affairs (at least for the 
moment) (Moreira et al., 2005: 67).  A ‘parasitic’ relationship may be seen to exist 
between hope and truth, in developing innovative medical technologies and 
techniques, as ‘hope’ provides a foundation for (and may be also seen to be 
performative of)  investing efforts in order to secure the ‘truth’ that something 
good will come out of the research. The two articulating knowledges/regimes of 
hope and truth are seen to be in flux in biosciences: but more specifically it is the 
articulation of the relationship between them that is in flux (Moreira et al., 2005). 
 
For Brown (2006) the ‘will to the yet not present’ also serves as a basis for 
‘promissory abstractions’ that employ values, desires and aesthetics. Brown cites 
an example in which GM food developers modified their consumer message 
away from regimes of truth to regimes of hope – from using scientific evidence to 
promote their products to using the by-line ‚imagine‛ as the marketing message 
to advance the idea that ‚food, health and hope‛ underscores their development 
agenda. Marketing hope ties into what has elsewhere been described as a shift 
from authority to authenticity (Brown et al., 2002). In regimes of hope not only 
the messages are different, but also crucially, aspects of subjectivity. Moreira and 
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Palladino (2005) consider how orienting to a regime of hope also views and 
constitutes patients as more invested in securing a different and positive future 
for themselves, whilst appeals to ‘truth’ leave no space or time for its deferral.  
 
Financing biomedical research; enabling the capital investments in hope creates  
new spaces for research, new kinds of subjectivities and forms of engagement, 
but also  raises the spectre of hype and the ‚damaging implications of failed 
futures‛ (Brown, 2003: 5). The promise of biotechnology, of genetic engineering,   
transgenics, bioinformatics, probiotics, probiotics, synbiotics and so on – if 
oriented in hope also establish the potential for disillusionment when too much 
is invested in the expectation of their success.  The dynamics of expectation, may 
as Brown suggests, create a need for more workable expectations in relation to 
biotechnology: 
 
The problem with the biotechnology sector is that, like many areas of innovation, 
expectations are sometimes both inflexible and reflect disproportionately 
exaggerated benefits and risks. This occurs for the very reason that future-
abstractions are put into circulation in the first place – to have a ‘performative’ 
influence in real time (Brown, 2003: 6). 
 
The double-bind of expectations is established: the shift to a more hopeful tense 
establishes the potential for failure, but also enacts a performative function in 
manifesting hopes in practical and material form that may well produce positive 
future outcomes. Moreover, as Novas (2006) considers, in a political economy of 
hope subjects who have until now, been left out of a direct priority setting role in 
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biomedical research may be empowered and enabled to direct research towards 
the aspirational futures of significance to them.  
 
Thus far, our discussion has centred on the tensions between regimes of hope 
and truth in particular relation to biomedicine. The case of probiotics offers a 
somewhat different vantage point from both the biomedical accounts so far 
presented, as well as debates about innovative technologies in consumer culture. 
In consumer culture, research that might be said to be concerned with hope and 
truth (often cast as hype and truth)  have tended to focus on examples where 
there is a high degree of public scepticism – a prominent example being 
genetically-modified (GM) foods (Brown, 2006; Cook, Pieri and Robbins, 2004; 
Cook, Robbins and Pieri, 2006). The GM debate has been typified by the hopeful 
futures suggested by industry (backed by scientific evidence) and the way in 
which they are sometimes consumed as unsatisfactory truths for a sceptical 
public. First, it is not the presence of scepticism in the public sphere but the lack 
that intrigues in relation to probiotics. Second probiotics biovalue seems more 
highly regarded in consumer settings than in biomedicine. If the articulation of 
relationships between hope and truth may be said to vary between biomedicine 
and consumer markets, it may also be that parasitism can be investigated as 
spatially constituted. In short, probiotics provide an empirical case study through 
which to examine how different spatialities deploy different configurations of hope and 
truth. 
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In what follows we examine three spatial aggregations of actors and their 
representations of hopes and truth about probiotics. The first takes as its point of 
departure an extensive review of the status of probiotics in biomedicine. The 
second occurs in an intermediary space of the media through an examination of 
an interaction between different publics and scientists in which public actors 
respond to a scientific review of probiotics. Finally we take the examination into 
consumer culture and consider how two lead producers of probiotic ‘little 
bottles’ market their products to the public.  
Probiotic expansions – the future of medicine? 
 
Are probiotics the future of medicine? Theoretically, beneficial micro-organisms 
could be used to treat a range of clinical conditions that have been linked to 
pathogens, including gastrointestinal problems like irritable bowel syndrome and 
inflammatory bowel disease…oral diseases like tooth decay and peridontal 
disease, and various other infections. Probiotics could also conceivably be put to 
use in preventing disease or thwarting autoimmune disorders (Walker et al., 2006: 
3).  
 
The quote above introduces a report by the American Academy of Microbiology 
and is based on a colloquium held in 2005 on the topic of probiotics. The 
colloquium included 38 participants from fields as diverse as microbiology, 
medicine, animal science, immunology and nutrition amongst others; and from 
the UK, Canada, Australia, the Netherlands, Finland, Germany as well as the US.  
The report is titled Probiotic microbes: the scientific basis, a title which establishes 
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the tone of what we expect will follow, a description of the ‘truth’ about what is 
known. Indeed the report is premised on the recognition that, an ‚evaluation of 
the current state of knowledge about probiotics is required‛(3). The report 
suggests:  
 
The buzz about probiotics has become a roar. But what can beneficial 
microorganisms really accomplish? Can these products benefit human 
or animal health? When it comes to probiotics, what is real and what 
is fiction? (Walker et al., 2006: 5). 
 
Despite the appeal to truth signified by the title and elements of the quotes 
above, is also oriented towards the potential future benefits that probiotics might 
provide for a range of clinical conditions and preventive options. The 
introductory sections of the report are filled with prospective terminologies that 
align with a regime of hope: ‚theoretically‛, ‚conceivably‛, ‚possibilities‛, 
‚exploration‛, ‚could reduce the risk‛, ‚potential effect‛, ‚could have beneficial 
outcomes‛ and so on. The effect is not to discount hope, but rather to establish 
what is regarded as (yet) untrue or as fiction.   
 
In what follows is a listing of different conditions, the research on probiotics and 
the limited, but nevertheless promising evidence-base that probiotics might have 
uses for a series of target disorders: diarrhoea, pouchitis, irritable bowel 
syndrome, bladder cancer, urogential infections, clostridium difficile infection, 
atopic eczema. Based on this evidence the report then lists the potential future 
applications for therapeutic treatments, the limits of the evidence and inherent 
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difficulties in measuring and universalizing the results.  The complexity of the 
gut and of microorganisms and their variable effects within it renders any 
appeals to ‘truth’ metered by the lack of a similarly complex evidence-base.  
 
In short, the report of the American Microbiological Association attempts to 
draw a shared truth about probiotics from a diversity of scientific actors engaged 
in a controversy.  Moreira and Pallandino (2005) demonstrate how aggregations 
of actors occur around regimes of hope and truth. The power of the aggregation 
appears greater than the sum of its parts, thus it is through the coming-together 
of different actors that stabilizes further the appeal to a regime of truth.  
 
However, although the report is directed to settle the controversy over 
effectiveness through appeals to truth, it also appeals to a hope of something 
good coming out of the research that is necessary to move beyond this. Fiction 
becomes a metaphor for hype, but also discounts the performative function of 
futurity in stabilizing the future research agenda.  Securing resources, 
demonstrating the need for research is necessarily premised on hope, but there is 
no authoritative space for such fantasizing in a regime of truth.  The parasitic 
relationship that is established justifies the need for research (on the hopeful 
predictions about what might be possible)  precisely because the ‘truth’ is not 
known. By the end of the report it is the lack of truth that provides the key 
rationale for financing future research, the final recommendations list areas of 
uncertainty, suitability of testing procedures and the need for robust evidence: 
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There is a pronounced need for large, carefully designed (randomized, placebo 
controlled) clinical trials of probiotics that undertake broad sampling of host 
microbiota, have clear end points, and have well informed participants who 
consent to treatment. Investigations like these are needed to overcome the placebo 
effect and other barriers to the thorough investigation of probiotic products 
(Walker et al., 2006: 19). 
  
The parasitic relationship between hope and truth is in effect, a masterful bait 
and switch. The bait is an appeal to truth, but the switch is that hope about their 
potential is the underlying trope that the report eventually succumbs to. It is 
apparent however that the authors themselves do not align with a regime of 
hope even as they employ it, but rather see themselves as the truth seekers.   
 
We now turn to a different aggregation of actors in which science is challenged 
by those ‘outside’ the biomedical realm. 
Hope in the supermarket – truth in the lab? 
A commentary piece on probiotics that appeared in the British Medical 
Journal(BMJ) demonstrates how different actors deploy hope and truth in ways 
that do not augur well for agreement. Here we compare a science commentary 
on probiotics with a series of rapid responses published in the BMJ over the 
following year and a half. 
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Science editor of the BMJ, Abi Berger, wrote a short commentary on probiotics 
that provoked a flurry of critical responses from readers (Butler, 2002; Hayden, 
2003; Leger, 2002; McClain, 2002). Berger described probiotics as microbes that 
could in some cases prevent disease in the host and commented on their 
promising results in preventing diarrhoea and atopy (allergic reactions where 
there is no direct contact between the allergen and effect; such as eczema) in 
children. He suggested that while it was known that antibiotics modify the 
composition of the flora of the gut, and diarrhoea was one consequence of that, it 
was still not clear that probiotic supplements could act to substitute for such 
losses. Although promising, Berger suggested that there was still much to be 
learned about probiotics because of the complexity of the gut and related 
uncertainties about how they worked, and the lack of studies providing sufficient 
evidence of efficacy. Berger’s truth about probiotics was far from unhopeful, but 
rather emphasised ‘that which is known’ over the more prospective, but 
nevertheless hopeful truth that there was more to be learned. Nevertheless, four 
responses critical of the commentary were aired that signalled dissatisfaction 
with the ‘truth’ as presented. 
 
A journalist responded with a critique arguing that: 
 
 …for years, I have watched the medical profession floundering around on the 
issue of probiotics. There seems to be a philosophy that anything is only ‘useful’, if 
it is clinically proven to be useful. Even more so, if ‘we’ say so (Butler, 2002). 
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 The position is one of fault finding, not with probiotics per se, but with the 
authority of science and the modes through which scientists engage with the 
world. The author defers truth about probiotics by emphasising uncertainty and 
using it as a justification for far greater investment in hope.  
 
A natural health consultant expresses ‚delight‛ at the new scientific interest in 
probiotics , ‚even if it seems moot to the cultured kefir-eaters among us‛ (Leger, 
2002). Kefir is a fermented milk product that is linked with a long history of use 
in the Caucasus and is highly regarded amongst Complementary and Alternative 
Medical communities (CAM). Tradition, experience and history provides a truth 
about an example of a product containing various bacteria that slot nicely into 
the probiotic category, but the example of kefir is used to demonstrate the truth 
about the category as a whole. Truth is not linked directly to probiotics, but to a 
more complex set of associations in which demonstration of efficacy is not 
clinically proven, but is made evident through the association of a diverse set of 
people united as, ergo healthy,  kefir-eaters. 
 
A specialist lactation consultant questions the profiteering of companies 
patenting bacterium found in fecal samples of babies for eventual use in formula 
feeds, and suggest that the properties have been ‚appropriated‛ by researchers 
who are paid by commercial interests to be used in products that may even 
‚sabotage‛ breastfeeding. She asks: 
 
 17 
Is the interest in probiotics the end result of scientific enquiry or the result of the 
patenting of these organisms by corporations seeking to turn a profit? (McClain, 
2002).  
 
The author deploys a regime of truth to question the role of capital in investing 
too heavily in hope, but moreover seeks ‘truth’  through alignments of nature, 
and particularly mother nature with health. That tendency to represent women 
and children, particularly babies as aligned to, or as a metaphor for, nature and 
health is far from a new observation (Stratford, 1998). 
 
Finally, a mother responds to the discussion with a personal story detailing her 
success with a probiotic treatment of her 5 month old baby’s eczema. She admits, 
‚I ignored my GP and health visitor when they suggested various creams and 
steroids‛ (Hayden, 2003). She seeks information from internet searches. Finding 
‘truth’ in internet information and grateful for the scientific articles already out 
there defending the value of probiotics, in this instance she does not defer truth 
so much as pre-empt it.   
 
The commentary and responses demonstrate different spatial configurations of 
truth and hope that play out in the development (or reconstitution) of 
biotechnologies. The ‘truth’ about probiotics in the biomedical sphere is also 
nested within regimes of hope about what they may achieve in treatment based 
outcomes. In the views of those responding negatively to the commentary, the 
truth may be constituted differently, or even through the same means, but with 
different effects. The tendency is for fault finding (deferring truth), but not 
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necessarily in relation to probiotics themselves – but other concerns – about 
scientific methods, other systems of belief like CAM, and personal experience. 
Thus it is not just how hope and truth may be associated with different actors in 
the controversy over effectiveness, but also what hope and truth relate to.  
 
The observation that innovation is situated ties to work in studies of science and 
technology, not about hope and truth, but concerning the ways in which interest 
in new biotechnological development often fails to take account of the context 
into which they are placed. It is all too easy in studies of biotechnology, suggests 
Bingham (2005) to focus on the novel innovation itself rather than exploring the 
surroundings in which such technologies necessarily emerge within and around. 
In this view, and drawing on the work of Mol (1993), Bingham argues that 
biotechnologies do not materialize in a void, but into a world already complex 
and full. ‘Things’ in the neighbourhood of biotechnologies, he suggests, can be 
investigated to give insights into where technologies, for example probiotic little 
bottles, fit. This seems appropriate for two reasons. First, as has been 
demonstrated thus far, the promise of probiotics is not simply different between 
actors but appears to have a spatial quality; it appears differently in biomedical 
and popular consumption sites. Second, what hope and truth refer to in the 
controversy about probiotics, is not necessarily probiotics themselves. Extending 
our theoretical approach in the following section, in which we look specifically at 
the case of little bottles, we consider actors, aggregations and hope and truth 
around probiotics in the supermarket, but also ask where (in the world) hope and 
truth emerge.  
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Between hope and truth and next to  
In this section we present key findings of a content analysis of advertisements 
from the two leading probiotic manufactures in the UK (Yakult and Danone 
Actimel) over a two year period (January 2005-January 2007); this includes 
advertisements from a range of different media including television, newspaper 
and the internet. Our interest was in exposing different articulations of hope and 
truth between science and popular consumption.  We therefore focused our 
investigation on how the leading probiotic companies might frame messages for 
popular consumption, and the coherence of such framings across a random 
sample of their advertisements (Krippendorff, 2004). A selection of from each 
company and genre (newspaper, internet video, internet text, television 
advertisements) were sampled at six monthly intervals.   While we utilised a 
content analysis method to ensure a consistent approach to the selections, our 
aim was not to prove assertions to be true or generalisable. Following Peirce 
(1958) and Eco’s (1976) account of abductive analysis where examination occurs 
not through simple deduction or induction but rather through a process of 
inference, insight, empirical observation (in this case of adverts) and logical 
reasoning to generate new understandings we present an argument for a 
particular explanation (cf. Iedema, 2007). We detail two fairly typical examples of 
these advertisements and refer to a few others to consider where hope emerges, 
next to what and associated with what promissory abstractions.  
 
Close up of a woman holding three videos she looks at the camera and says: 
‚Well in order to maintain my er wellbeing I’ve become completely dependent 
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on these er yoga videos‛.  As the camera pans out we see her placing the video’s 
on a pile of others and moving backwards into a relaxed seated position in a 
lounge chair drinking a bottle of Actimel; the camera gives a close up of the little 
bottle as the narrator in the background states ‚Only Actimel has the l.casei 
immuitas culture”. The camera returns to the woman lazing in the chair, she leans 
forward to place the little bottle on the pile of yoga videos and as she does so 
says ‚ stretch “, the narrator states:  the Actimel habit, keep it up”  the woman leans 
back in the chair and says ‚relax‛, the advertisement ends with the narration mm 
Danone2 
Box 1: Description of Yoga advertisement for Actimel (Danone, 2002) 
 
The advertisements about probiotics vary considerably in content, form and 
delivery, however common representations are, like the Actimel advertisement 
above, of individual consumers who need do very little to secure a desirable 
health state (Box 1). The appeal to regimes of truth lies in the authenticity of the 
particular bacterial culture that is used by the company Danone and, other than 
the appeal to make this a habitual activity, the company says nothing directly 
about the evidence of effectiveness or even what health states the person may 
seek to address by using the product. Rather, the woman herself embodies the 
                                                     
 
 
 
 
2 Viewed on a one off basis at http://www.uk.actimel.com/ 
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health state that is desired – one in which knowledge of yoga demonstrates her 
appreciation of the need for physical exercise, but where the placement of the 
now empty little bottle on top of the pile of videos signifies its effective 
replacement through consumption.  
 
The marketers aestheticize probiotics (Brown, 2006) deploying a vision of health 
and well-being. But such an aesthetic may also be seen to be nested within 
particular discourses of health. The sociological literature on ‘healthism’ 
(Crawford, 1980) is now more than two decades old, and yet observations about 
the shift from treatment oriented regimes of health to lifestyle interventions and 
ideas about healthy living still resonate in contemporary settings.  Bunton, Nettle 
and Burrows (1995) contribution to the sociology of health promotion sets out 
this transition. But it is worth returning to one of their key observations: with the 
shift in biomedical interest, there is a cultural shift to healthism. Healthism is 
seen to have a value beyond medicine that articulates with consumer culture in 
particular ways, most notably in the present through ideas of ‚youth, vitality, 
energy and so on‛ (Henderson and Petersen, 2002).  
 
Certainly youth, vitality and energy are routinely employed in many 
advertisements for probiotics. Indeed one probiotic ‘little bottle’ company 
markets their goods directly as  ‘Vitality’ (Müller Company).  Yet the aesthetic of 
one-slurp-well-being is not the only kind of engagement with the public – 
regimes of truth underscore much of the advertising for the Yakult company, 
albeit less for public consumption than for those publics that make the extra 
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effort to learn more about the product by visiting the  more detailed literatures 
available through the company websites. 
 
The index page for the Yakult company website in the UK provides the following 
text: 
 
Do you do something you believe in? Us too. Our little bottle. Full of good bacteria. 
To help your digestive system. Which can lead to better natural defences. Simple. 
Our founder Dr. Shirota certainly thought so; he dedicated his life to isolating a 
strain of bacteria beneficial to human health. He succeeded in 1935 and placed his 
unique bacteria into a milk drink so its benefits were accessible to all. Have a 
wander around our website to find out what Yakult can do for you 
(www.yakult.co.uk, accessed 14 January 2007) 
 
The content of the introductory statement about Yakult contains a series of 
declarative statements: our little bottle, full of good bacteria etc. Each of which 
can be examined individually in order to raise questions about what else in the 
world such concerns relate to. The following is a prospective analysis, and not 
one that necessarily can be verified without further examination – rather the 
discussion demonstrates probiotics little bottles emerge in a world that may be 
seen to be already complex and full (Bingham, 2006). 
 
The little bottle: both Yakult and Danone, as the biggest players in the probiotic 
drinks market in the UK, have used the unique packaging as a key element of 
their  marketing strategies and the use of ‘daily-dose’ formulas has been cited as 
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key element of the success of probiotics; as well as other goods packaged in little 
bottles (Mattila-Sandholm et al., 2002). The appeal of a little bottle may lie in 
convenience of a single serve, but it also accords with a language more common 
in the medical sphere in advocating particular dosage levels, taken regularly, as a 
means to achieve a health outcome. The little bottle may in fact, appeal to both a 
regime of truth in its medical guise, and exist within a regime of hope in aligning 
with a contemporary concern for convenience. Put another way, the little bottle is 
not the same thing if entangled in regimes of hope or of truth. The qualities of the 
little bottle are different in an ontological sense, changing in different regimes 
and settings. 
Good bacteria: ‘good’ and its obvious opposite ‘bad’ create an all-too simplistic 
image of right and wrong that belies any question of complexity that is so much a 
feature of the biomedical investigation of probiotics and their variable effects. 
Though all too black and white, the appeal in marketing may not be about 
probiotics per se, but rather lie for example,  in a new awareness that not all 
bacteria have negative health effects. Such a shift in thinking may in turn have 
been precipitated by concerns about anti-microbial resistance and the over-use of 
antibiotics and public health campaigns to raise awareness of the issue 
(Department of Health, 2000). Though we do not wish to make the claim that 
probiotics are successful because of public awareness of anti-microbial resistance, 
awareness of both has certainly risen in the same time frame – perhaps 
warranting further investigation of a link. 
Help digestive system, better natural defences: There is strong association between 
probiotics and securing the body against that which is outside using individuals’ 
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seemingly innate immunity. The contemporary concern with personal security 
has resonances with the threats not only to individuals, but to nations as a whole. 
The global threat of terrorism, biological warfare and so on, provide as Brian 
Massumi suggests, a ‘background hum of anxiety’ that pervades every aspect of 
human activity (Massumi, 1993). The notion of ‘balance’ is another element 
commonly invoked in the advertisements for probiotic little bottles: ‘restoring 
balance’, ‘maintaining balance’ and in general, reordering relations between 
humans and their internal flora. Balance, like immunity, functions as a 
metaphorical device associated with inside and outside, self and society. 
However consider the following statement from one probiotic company:  ‚As we 
all try to juggle increasingly hectic lifestyles, it’s often difficult to maintain a 
healthy diet‛: here balance refers to lifestyle factors and their influence on diet. In 
this view, consuming probiotics may be part of the solution to imbalances in 
lifestyle – and ones that can be remedied not by changing lifestyle practices, but 
by adding new elements to the diet. 
Simple: A magic bullet? The marketers do not explain why Yakult or probiotics 
should be regarded as simple and unambiguously good for health, but they do 
offer a method by which to accept this simple ‘truth’. The paragraph tells the 
story of Dr Shirota, a man who we should believe in because as ‘they’ suggest, 
they do. The product is marketed through appeals to authenticity derived from 
the portrayal of an eminent scientist and founding figure – a man that embodies 
a regime of truth. 
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In short probiotics establish a new foundation upon which to measure health and 
through which to establish hope and truth about them; in particular through the 
notion of the body in imbalance. The ‘truth’ that is established is of a new kind of  
acceptance that however much harmony bodies are capable of, the essential 
disharmony of modern living renders us unable to live without added health. 
One question arising from the consumption of probiotics is then what kind of 
subjectivities does this give rise to? Isin (2004) has argued that such disharmonies 
are symptomatic of the emergence of a new kind of ‘neurotic’ subject:  ‚while on 
the one hand neurotic subjects are incited to manage their anxieties by adjusting 
their conduct, they are also incited to administer themselves with pharmaceutical 
interventions without making adjustments to conduct‛(226). The neurotic subject 
of probiotic consumption feeds within regimes of hope that are in turn, fed by 
appeals to regimes of truth. 
Discussion and conclusion: on hope truth and geography 
We have not implicitly discussed how geography might be used to think about 
regimes of hope and truth, however by dividing our discussion into three 
sections that detail different aggregations of actors we have located them 
differently and found similarities in each aggregation in the ways that hope and 
truth play out. Brown(2006: 4) observes that ‚uncertainties become less visible 
the further one travels in space and time from the material messiness of the 
bench‛ and that for this reason,  regimes of hope and truth might be thought of 
as spatially and temporary patterned. The public acceptance of probiotics does 
seem to provide an example where distance from the bench erodes the messy 
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uncertainties about the ‘truth’ of them: and almost entirely.  However in our 
view it is more than distance from uncertainty that may be considered in this 
spatial patterning; we observe that the form of parasitic relation between regimes 
of hope and truth are also spatially patterned.  
 
The observation of Tannock, raised in the introduction, that probiotics may be 
consumed as an ‘article of faith’ in the supermarket, provides a clue that the 
subject constituted by and within spatial regimes of hope and truth as the lynch-
pin of the kinds of parasitism that emerge. The promissory abstractions of 
simplicity, immunity, self-defence, well-being and so on, are premised on the 
subject being situated outside biomedicine. In contrast, while the articulation of 
the relationship between regimes of hope and truth may be shifting within 
biosciences, the subject sill maintains the ‘self’ through a regime of truth – as 
suggested, there is no place for promissory abstractions in the laboratory. Put 
another way, there is no place for a new kind of subject constituted within 
regimes of hope within the laboratory.  
 
In our examination we have considered how the notion of regimes of hope and 
truth might be useful for thinking about how different aggregations of actors 
engage in a controversy about the biovalue of probiotics. We conclude that 
focusing only on the object of our investigation, probiotics, is not sufficient to 
explain where the promise of probiotics resides.  Using the example of company 
advertising about them we sought to uncover some plausible, though untested, 
reasons that regimes of hope and truth apply to much broader concerns than 
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simply the development of the innovative product itself.  For us, the 
development of priobiotics is symptomatic of the new spatial formations 
common to contemporary public health: the supermarket and home as more than 
places where food gets bought and prepared, but where ideas about health and 
illness are increasingly reside. We concur with others that there is a spatial 
patterning to regimes of hope and truth, but suggest new approaches are 
required to consider the significance of shifting balance between the articulation 
of truth and hope and its spatial patterning.  
 
In practical terms, our examination of probiotics provides some further insight 
into their marketing success, also suggesting there is more to their appeal that 
particular health gains. Probioitics articulate a range of contemporary discourses 
about health that include those from within biomedicine, but also in terms of a 
public health focus on lifestyle and the cultural appeal of healthism; amongst 
other less easily identified values and aesthetics. Their appeal is multifarious and 
complex. The category of functional foods appears to conflate health with 
evidence based medicine and offers a range of new products for consumers in 
these terms, however the success of probiotics in relation to other functional 
foods provides some indication that probiotics articulate more than ‘simply’ 
biomedical concerns.  
 
Finally, we raised some concerns about the new subjectivities that emerge from 
these discussions. In our analysis the biomedical subject remains one driven by 
rational enlightenment thinking, despite the new salience of hope in driving 
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innovations forward within the laboratory. However the consumer does appear 
differently - forged through an expectation of disharmony.  
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